Recrutement en cours

H4HÉtablissement de normes de référence d'empreinte moléculaire pour le vieillissement en bonne santé et la transition de la maladie

0 critères remplis à partir de votre profilVoyez en un coup d'œil comment votre profil répond à chaque critère d'éligibilité.
But de l'étude

Cette étude observationnelle vise à établir des normes de référence pour le vieillissement en bonne santé et la transition vers la maladie en suivant les participants dans le temps, dans le but d'identifier de nouveaux biomarqueurs pour la maladie coronarienne, le cancer du poumon et le diabète de type 2 à l'aide de méthodes d'analyse riches en contenu d'information.

Ce qui est collecté

Collecte de données

Données recueillies dès le début de l'étude - Prospective
Avec prélèvements ADN
Qui peut participer

Maladies Occlusives des Artères+37

+ Artériosclérose

+ Maladies du cerveau

À partir de 40 ans
Voir tous les critères d'éligibilité
Comment se déroule l'étude

Cohorte

Suivi d'un groupe de personnes dans le temps pour mieux comprendre les causes et l'évolution d'une maladie.
Observationnel
Date de début : juillet 2021
Voir le détail du protocole

Résumé

Sponsor principalCenter for Molecular Fingerprinting Research Nonprofit LLC
Contacts de l'étudeCenter for Molecular FingerprintingVoir plus de contacts
Dernière mise à jour : 3 août 2026
Issu d'une base de données validée par les autorités. Revendiquer en tant que partenaire

Date de début de l'étude : 27 juillet 2021

Date à laquelle le premier participant a commencé l'étude.

BACKGROUND The H4H study monitors health changes for 10 years in participants who are healthy at the outset but are at risk to develop new-onset health conditions. It uses a prospective study design and encompasses over 100,000 person-years of follow-up, allowing close observation of disease trajectories in relation to risk factors and medication use. This provides a unique opportunity to collect data on current tendencies in non-communicable disease (NCD) presentation and management. Major NCDs (i.e., cardiovascular disease, cancer, type 2 diabetes and chronic respiratory disease) cause a significant loss in quality of life and are responsible for over 90 percent of Hungary's all-cause mortality. Therefore, there is growing demand for screening tools that might be used at minimal expense to reduce the overall burden of diseases. 'Early diagnosis' and recognition of high-risk states prior to the development of overt clinical diseases would allow better therapeutic outcomes and help preserve quality of life longer in the society. Blood tests are valuable screening tools for many conditions and may be used for population health monitoring. Better understanding of blood composition, along with establishing reference ranges for blood constituents, is essential for developing effective blood-based health monitoring strategies. High-information-content detection methods, including molecular fingerprinting, proteomics and metabolomics are expected to promote the discovery of novel disease biomarkers. By assessing a wide range of molecules, multiple disease-specific variables may be recognized. Apart from multimodal analysis of blood samples, aliquots of all samples are preserved in a dedicated biobank with a commitment to accommodate a comprehensive collection of biospecimens for decades and to facilitate long-term research arrangements with the intention to accelerate future discoveries. OBJECTIVES The study aims to address the following objectives: A) Establish reference ranges for infrared molecular fingerprinting and other high-information-content analysis methods (i.e., proteomics and metabolomics) in a non-symptomatic population using a cross-sectional approach. B) Define characteristics of healthy aging and establish personalized reference intervals for infrared molecular fingerprinting and other high-information-content analysis methods using a longitudinal approach. C) Identify novel biomarkers for non-communicable diseases, including coronary artery disease, lung cancer and diabetes, using infrared molecular fingerprinting and other high-information-content analysis on blood samples. D) Identify novel blood-based risk factors for non-communicable diseases and discover indicators of precursor diseases using infrared molecular fingerprinting and other high-information-content analysis methods. The findings of the current study will be instrumental in identifying disease specific deviations of human blood composition. This could lead to the discovery of 'novel biomarkers'. Overall, the study will determine whether the molecular composition of human plasma remains stable over time and will test whether deeper analysis of blood samples can form the basis of population health monitoring. STUDY DESIGN The project is conducted in a single-country, multicenter, prospective, longitudinal format. Sample collection is scheduled for ten years according to this protocol. PARTICIPANTS The study enrolls healthy subjects of > 40 years or > 50 years in low- or high-risk cohorts, respectively, who are followed up for ten years. Enrollment continues until 15,000 subjects are enrolled. PROCEDURES: Blood sample collection occurs in accordance with the clinical routine and plasma samples are processed for high-information-content analysis. Additional blood tubes are submitted to clinical laboratory testing. Health data collection utilizes self-report questionnaires and review of medical records. In the high-risk cohort, a comprehensive medical examination is performed after the first 4 blood samples are collected, including screening tests for lung cancer and coronary artery disease, i.e., a low-dose CT scan of the chest and coronary artery calcium score test (heart scan). These investigations are repeated after a follow-up period of 5 years. WITHDRAWAL OF CONSENT, DISCONTINUATION FROM THE STUDY Participation in this sample and data collection project is voluntary, and each participant has the right to withdraw their consent at any time without any consequence concerning possible future treatment or future blood donations.

Sponsor principalCenter for Molecular Fingerprinting Research Nonprofit LLC
Contacts de l'étudeCenter for Molecular FingerprintingVoir plus de contacts
Dernière mise à jour : 3 août 2026
Issu d'une base de données validée par les autorités. Revendiquer en tant que partenaire

Protocole

Cette section fournit des détails sur le plan de l'étude, y compris la manière dont l'étude est conçue et ce qu'elle évalue.
Détails du design

15000 participants à inclure

Nombre total de participants que l'essai clinique vise à recruter.

Cohorte

Ce type d'étude observe, sur une période définie, un groupe de personnes partageant une caractéristique commune (comme une maladie ou une année de naissance), afin d'analyser leur état de santé ou leur exposition à certains facteurs.


Éligibilité

Les chercheurs recherchent des patients correspondant à une certaine description appelée critères d'éligibilité : état de santé général ou traitements antérieurs du patient.
Conditions
Critères

Tout sexe

Le sexe biologique des participants éligibles à s'inscrire.

À partir de 40 ans

Tranche d'âge des participants éligibles à participer.

Volontaires sains autorisés

Indique si les individus en bonne santé et ne présentant pas la condition étudiée peuvent participer.

Conditions

Pathologie

Maladies Occlusives des ArtèresArtérioscléroseMaladies du cerveauNéoplasmes bronchiquesCarcinome bronchogéniqueMaladies du système nerveux centralTroubles cérébro-vasculairesMaladie chroniqueMaladie coronarienneMaladies du système endocrinienMaladies CardiaquesMaladies pulmonairesMaladies pulmonaires obstructivesMaladies métaboliquesNéoplasmes par siteMaladies du système nerveuxMaladies nutritionnelles et métaboliquesProcessus pathologiquesMaladies des voies respiratoiresNéoplasmes des Voies RespiratoiresConditions pathologiques, signes et symptômesNéoplasmes thoraciquesMaladies vasculairesMaladies vasculaires périphériquesIschémie myocardiqueAttributs de la maladieTroubles du métabolisme du glucoseMaladies non transmissiblesCarcinome du poumon non à petites cellulesMaladies CardiovasculairesMaladie coronarienneDiabète MellitusDiabète sucré de type 2Néoplasmes pulmonairesNéoplasmesÉtat prédiabétiqueAccident Vasculaire CérébralMaladie pulmonaire obstructive chronique (MPOC)AthéroscléroseMaladie artérielle périphérique

Critères

Low- and Moderate-risk Cohort: Inclusion Criteria: 1. Signed informed consent form (ICF) of the study. 2. Age \> 40 years. 3. Willingness to fill in the study questionnaire. 4. No clinically relevant symptoms as assessed by the investigator, subjects with existing medical conditions may be eligible given that they are symptom free and that full treatment of the condition is medically confirmed. 5. Willingness to participate in future visits. Exclusion Criteria: 1. Self-reported pregnancy (no test). 2. Indications of clinically relevant medical conditions in self-reported healthy subjects. 3. Self-reported symptom-free HIV, HCV and HBV infections. If HIV, HBV or HCV serology test is done and any of them are positive, the subject will be considered a screen failure. 4. Any conditions preventing blood-draw. 5. Vulnerable subjects. 6. Foreseeable lack of compliance. 7. Participation in another sample collection project of the same sponsor, in order to avoid double evaluation of the same subject. 8. Participation (currently or in the past month) in an early phase clinical trial (phases I and II) involving testing of pharmaceutical products, if the last dose of pharmaceutical product administration was within 30 days of the first sample collection, and / or further pharmaceutical product administration is planned. 9. Vaccination within the last 14 days. High-risk Cohort: Inclusion Criteria: 1. Signed informed consent form (ICF) of the study. 2. Age \> 50 years. 3. Willingness to fill in the study questionnaire. 4. Willingness to participate in future visits and medical investigations, the presence of at least 2 of the following 3 risk factors (inclusion criteria #5-7): 5. Hypertension, receiving antihypertensive treatment. 6. Dyslipidemia/ Hypercholesterolemia (\>5.2mmol/L total cholesterol level), on or not on statin-treatment. 7. Active or former smoker, with smoking history of at least 20 pack-years, and/or the presence of intermediate lung nodule on prior LDCT testing. 8. No clinically relevant symptoms as assessed by the investigator; subjects with existing medical conditions may be eligible given that they are symptom free and that treatment of the condition is well documented. Exclusion Criteria: 1. Self-reported pregnancy (no test). 2. Cardiovascular disease (including obstructive coronary artery disease, peripheral artery disease, aortic aneurysm) or other clinically significant heart disease (congenital, valvular heart disease, cardiomyopathy, heart failure and heart disease requiring ICD \[implantable cardioverter defibrillator\] or pacemaker therapy). 3. Interstitial lung disease or severe COPD (chronic obstructive pulmonary disease) in GOLD stages 3 or 4. 4. Active cancer or malignant disease with less than 5 years history of remission. 5. Indications of clinically relevant medical conditions in self-reported healthy subjects, especially if (a) the condition requires regular or constant specialist checkups, or (b) pharmacological therapy indicates the presence of significant NCDs or multimorbidity, i.e., chronic polypharmacy (use of 5 or more medications at enrollment or over the last 6 months), or drug therapy necessitating a specialist input for initiation or management (e.g., combined anti-diabetic treatment with two or more medications). 6. Self-reported symptom-free HIV, HCV and HBV infections. If HIV, HBV or HCV serology test is done and any of them are positive, the subject will be considered a screen failure. 7. Any conditions preventing blood-draw or CT scans. 8. Vulnerable subjects. 9. Foreseeable lack of compliance. 10. Participation in another sample collection project of the same sponsor, in order to avoid double evaluation of the same subject. 'High-risk' subjects enrolled in the low- and moderate-risk arm of the H4H study might be reallocated to the high-risk study arm after the first 4-5 visits. 11. Participation (currently or in the past month) in an early phase clinical trial (phases I and II) involving testing of pharmaceutical products, if the last dose of pharmaceutical product administration was within 30 days of the first sample collection, and/or further pharmaceutical product administration is planned. 12. Vaccination within the last 14 days of sample collection.

Plan de l'étude

Découvrez tous les traitements administrés dans cette étude, leur description détaillée et ce qu'ils impliquent.
Groupes de traitement
Objectifs de l'étude

2 groupes d'intervention sont désignés dans cette étude

Cette étude ne comporte pas de groupe placebo. 

Groupes de traitement

Objectifs de l'étude

Objectifs principaux

Objectifs secondaires

Centres d'étude

Ce sont les hôpitaux, cliniques ou centres de recherche où l'essai est conduit. Vous pouvez trouver le site le plus proche de vous ainsi que son statut.

Cette étude comporte 33 sites

Recrutement en cours

14_TP Békéscsaba_Trial Pharma LLC Békéscsaba

Békéscsaba, HungaryOuvrir 14_TP Békéscsaba_Trial Pharma LLC Békéscsaba dans Google Maps
Recrutement en cours

31_TP Szt Magdolna_Trial Pharma Ltd. Magdalene Private Hospital

Budapest, Hungary
Recrutement en cours

08_Qualiclinic Budapest_Qualiclinic LLC

Budapest, Hungary
Recrutement en cours

22_MÁV Budapest_Railway Health Care Nonprofit Public Benefit Ltd.

Budapest, Hungary
Recrutement en cours
33 Centres d'Étude